Abingdon Health PLC Notice of AGM and Notice of Results (2789H)
November 23 2022 - 1:44AM
UK Regulatory
TIDMABDX
RNS Number : 2789H
Abingdon Health PLC
23 November 2022
Abingdon Health plc
("Abingdon Health", the "Group" or the "Company")
Notice of Annual General Meeting and Notice of Results
York, U.K. 23 November 2022: Abingdon Health plc (AIM: ABDX), a
leading international developer and manufacturer of high quality,
rapid diagnostic tests, announces that its Annual General Meeting
('AGM') will be held on Monday 19 December at 9.30 a.m. at the
offices of Abingdon Health, York Biotech Campus, Sand Hutton, York,
YO41 1LZ, United Kingdom. Furthermore, the Company will be
releasing its preliminary results for the year ended 30 June 2022
on 24 November 2022.
The notice convening the AGM will be sent to shareholders today
and is available on the Company's website www.abingdonhealth.com
.
Enquiries:
Abingdon Health plc www.abingdonhealth.com/investors/
Chris Yates, Chief Executive Officer Via Walbrook PR
Melanie Ross , Chief Financial Officer
Chris Hand, Non-Executive Chairman
Singer Capital Markets (Sole Broker Tel: +44 (0)20 7496 3000
and Nominated Adviser)
Peter Steel, Alex Bond (Corporate Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
Paul McManus / Phillip Marriage Mob: +44 (0)7980 541 893 / +44 (0)7867
Alice Woodings 984 082
+44 (0)7407 804 654
About Abingdon Health plc
Abingdon Health is a world leading developer and manufacturer of
high-quality lateral flow rapid tests across all industry sectors,
including healthcare and COVID-19. Abingdon is the partner of
choice for a growing global customer base and takes projects from
initial concept through to routine and large-scale manufacturing
and has also developed and marketed its own labelled tests.
The Company offers product development, regulatory support,
technology transfer and manufacturing services for customers
looking to develop new assays or transfer existing laboratory-based
assays to a lateral flow format. Abingdon Health aims to support
the increase in need for rapid results across many industries and
locations and produces lateral flow tests in areas such as
infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access
to results allows for rapid decision making, targeted intervention
and can support better outcomes. This ability has a significant
role to play in improving life across the world. To support this
aim Abingdon Health has also developed AppDx(R) , a customisable
image capturing technology that transforms a smartphone into a
self-sufficient, standalone lateral-flow reader.
Founded in 2008, Abingdon Health is headquartered in York,
England.
For more information visit: www.abingdonhealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAFFFLLLTLFFIF
(END) Dow Jones Newswires
November 23, 2022 02:00 ET (07:00 GMT)
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Apr 2024 to May 2024
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From May 2023 to May 2024